| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 19.3MM | +9% |
| Gross Profit | 14.4MM | +11% |
| Cost Of Revenue | 4.9MM | +5% |
| Operating Income | -13.9MM | -8% |
| Operating Expenses | 28.3MM | +0% |
| Net Income | -13.9MM | -7% |
| R&D | 3.9MM | -8% |
| G&A | 24.4MM | +2% |
| Amortization | -200K | -300% |
| Interest Expense | 904K | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
REDWOOD CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 1, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “Inve
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company’s Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an except
REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today announced the inducement grant of equity awards to Steve Williamson, its newly-hired President and Chief Executive Officer, in accordance with Nasdaq Listing Rule 5635(c)(4). On March 15, 2024, Pulmonx granted Mr. Williamson (i) 205,286 time-based restricted stock units, which will vest as to 25% of such
Steven Cohen (Trades, Portfolio)'s Point72 Asset Management has recently made a notable addition to its investment portfolio by acquiring additional shares in Pulmonx Corp (NASDAQ:LUNG). The firm now holds a 5.00% stake in Pulmonx Corp, representing 0.04% of its investment portfolio. Steven A. Cohen, the Chairman and CEO of Point72 Asset Management, is a prominent figure in the investment world.
REDWOOD CITY, Calif., February 26, 2024--Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), today announced the treatment of the first patient in the CONVERT II Pivotal Trial, a multicenter, international study evaluating the safety and effectiveness of the AeriSeal® System in limiting collateral ventilation in severe COPD/emphysema patients. Collateral ventilation is caused by openin
One of the biggest stories of last week was how Pulmonx Corporation ( NASDAQ:LUNG ) shares plunged 25% in the week...
Pulmonx ( NASDAQ:LUNG ) Full Year 2023 Results Key Financial Results Revenue: US$68.7m (up 28% from FY 2022). Net loss...
Pulmonx Corporation (NASDAQ:LUNG) Q4 2023 Earnings Call Transcript February 21, 2024 Pulmonx Corporation beats earnings expectations. Reported EPS is $-0.36, expectations were $-0.39. LUNG isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. […]
Q4 2023 Pulmonx Corp Earnings Call
Year-Over-Year Revenue Climbs 28% in 2023, Gross Margin Remains Strong